NCT03109288View on ClinicalTrials.gov

Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

August 11, 2017

Primary Completion Date

January 1, 2026

Study Completion Date

January 1, 2029

Conditions
Multiple Sclerosis
Interventions
DRUG

Pioglitazone

15-45 mg po qd

DRUG

clemastine fumarate

8 mg/day (divided into 3 doses of 2, 2, and 4 mg)

DRUG

Dantrolene

Up to 200 mg/day (divided into 3 doses of 50mg, 50mg, and 100 mg)

DRUG

Pirfenidone

"Up to 801 mg po tid. Slow titration over weeks based on tolerability:~267mg po tid x \>= 7d 534 mg po tid x \>= 7d 801 mg po tid"

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH